Thursday, April 21, 2011

An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia

Sponsor: Murdoch Childrens Research Institute
Collaborator: Friedreich Ataxia Research Alliance
Principal Investigator: Martin Delatycki, MBBS PhD, Murdoch Childrens Research Institute
ClinicalTrials.gov Identifier: NCT01339884


"The purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters."

Excellent in-depth explanation of Friedreich Ataxia for all public

In the CAFA - Claude St-Jean Foundation website can find this diaporama where Dr. Jacques P. Tremblay, Ph.D., professor in the Department of Molecular Medicine of Laval University in Quebec and main investigator at the Research Centre of Quebec city (CHUL) makes an excellent explanation of the genetic and molecular basis of disease, in addition to a review of current major research directions.
It is difficult for an expert explain biological mechanisms as a layman, but Dr Tremblay gets a high-level explanation that can be understood by everyone without having much knowledge in life sciences.

Download the diaporama (20 Mb)